#
Brimonidine (EENT)
  • Professionals
  • AHFS Monographs

Brimonidine (EENT)

Class: alpha-Adrenergic Agonists
ATC Class: S01EA05
VA Class: OP109
Chemical Name: [S-(R*,R*,)]-2,3-Dihydroxybutanedioate-5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine
Molecular Formula: C11H10BrN5 • C4H6O6
CAS Number: 79570-19-7
Brands: Alphagan P, Lumify

Medically reviewed by Drugs.com on Dec 21, 2020. Written by ASHP.

Introduction

Relatively selective α2-adrenergic agonist.

Uses for Brimonidine (EENT)

Ocular Hypertension and Glaucoma

Brimonidine tartrate 0.1, 0.15, and 0.2%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Ocular hypotensive effect of the 0.1 or 0.15% solution is equivalent to that of the 0.2% solution; reduction in IOP was approximately 2–6 mm Hg in clinical studies.

Fixed-combination brinzolamide 1% and brimonidine tartrate 0.2%: Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. When administered 3 times daily, IOP-lowering effect was 1–3 mm Hg greater than that of either drug administered at the same dosage as monotherapy.

Fixed-combination brimonidine tartrate 0.2% and timolol 0.5%: Used topically in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy because of inadequately controlled IOP. When administered twice daily, IOP-lowering effect was 1–3 mm Hg greater than that of brimonidine tartrate 0.2% administered 3 times daily, 1–2 mm Hg greater than that of timolol 0.5% administered twice daily, and approximately 1–2 mm Hg less than that achieved with concurrent use of brimonidine tartrate 0.2% administered 3 times daily and timolol 0.5% administered twice daily.

When selecting an initial ocular hypotensive agent, consider extent of the required IOP reduction, coexisting medical conditions, and drug characteristics (e.g., dosing frequency, adverse effects, cost). With single-agent regimens, the reduction in IOP is approximately 25–33% with topical prostagl...